Tumor glycosylation epitope-specific radionuclide theranostic probes: review and prospect
10.3760/cma.j.cn321828-20250506-00137
- VernacularTitle:肿瘤糖基化表位特异性核素诊疗探针：回顾与展望
- Author:
Jin DING
1
;
Yuwen YANG
;
Teli LIU
;
Zilei WANG
;
Qian ZHANG
;
Feng WANG
;
Zhi YANG
;
Hua ZHU
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科、国家药监局放射性药物研究与评价重点实验室、放射性药物研究与试验评价北京市重点实验室、恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Publication Type:Journal Article
- Keywords:
Radiopharmaceuticals;
Mucin-1;
Glycosylation;
Diagnostic imaging;
Molecular targeted therapy;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(8):497-502
- CountryChina
- Language:Chinese
-
Abstract:
Glycosylation plays an important role in tumorigenesis and development. Mucoprotein-1 (MUC1), a transmembrane glycoprotein, is overexpressed in a variety of malignant tumors. The biochemical characteristics of tumor-specific short chain O-glycosylation (such as Tn/sialyl Tn (STn) antigens) are significantly different from those of normal tissue MUC1, which provides a molecular basis for precision diagnosis and treatment of tumors. This article systematically reviews the molecular design, clinical transformation progress and technical bottleneck of three types of probes targeting MUC1 glycosylation epitopes in tumors, including aptamers, peptides and monoclonal antibodies, focusing on their tumor uptake efficiency, targeting specificity and the potential of diagnosis and treatment integration, so as to provide theoretical basis for optimizing the clinical transformation path of MUC1 targeting probes.
